Loading...

We've got a brand new version of Simply Wall St! Try it out

Abattis Bioceuticals

CNSX:ATT
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ATT
CNSX
€20M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Abattis Bioceuticals Corp., a biotechnology company, researches, develops, licenses, and markets ingredients and formulas for use in the biopharma, nutraceutical, cosmetic, and animal nutrition markets in Canada. The last earnings update was 247 days ago. More info.


Add to Portfolio Compare Print
ATT Share Price and Events
7 Day Returns
0%
CNSX:ATT
1.6%
CA Pharmaceuticals
-0.1%
CA Market
1 Year Returns
-62.8%
CNSX:ATT
25.7%
CA Pharmaceuticals
3%
CA Market
ATT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Abattis Bioceuticals (ATT) 0% 0% 0% -62.8% 60% -
CA Pharmaceuticals 1.6% 4.9% 18.3% 25.7% 818.7% 575.5%
CA Market -0.1% 2.9% 6.6% 3% 15.5% 5.9%
1 Year Return vs Industry and Market
  • ATT underperformed the Pharmaceuticals industry which returned 25.7% over the past year.
  • ATT underperformed the Market in Canada which returned 3% over the past year.
Price Volatility
ATT
Industry
5yr Volatility vs Market

ATT Value

 Is Abattis Bioceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Abattis Bioceuticals. This is due to cash flow or dividend data being unavailable. The share price is CA$0.08.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Abattis Bioceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Abattis Bioceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:ATT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in CAD CA$-0.10
DB:115 Share Price ** DB (2019-02-04) in EUR €0.04
DB:115 Share Price converted to CAD reporting currency Exchange rate (EUR/ CAD) 1.506 CA$0.07
Canada Pharmaceuticals Industry PE Ratio Median Figure of 14 Publicly-Listed Pharmaceuticals Companies 24.84x
Canada Market PE Ratio Median Figure of 552 Publicly-Listed Companies 15.12x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Abattis Bioceuticals.

CNSX:ATT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:115 Share Price ÷ EPS (both in CAD)

= 0.07 ÷ -0.10

-0.63x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abattis Bioceuticals is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Abattis Bioceuticals is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Abattis Bioceuticals's expected growth come at a high price?
Raw Data
CNSX:ATT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.63x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 8 Publicly-Listed Pharmaceuticals Companies 1.39x
Canada Market PEG Ratio Median Figure of 255 Publicly-Listed Companies 1.19x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Abattis Bioceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Abattis Bioceuticals's assets?
Raw Data
CNSX:ATT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in CAD CA$0.17
DB:115 Share Price * DB (2019-02-04) in EUR €0.04
DB:115 Share Price converted to CAD reporting currency Exchange rate (EUR/ CAD) 1.506 CA$0.07
Canada Pharmaceuticals Industry PB Ratio Median Figure of 138 Publicly-Listed Pharmaceuticals Companies 3.09x
Canada Market PB Ratio Median Figure of 2,387 Publicly-Listed Companies 1.48x
CNSX:ATT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:115 Share Price ÷ Book Value per Share (both in CAD)

= 0.07 ÷ 0.17

0.39x

* Primary Listing of Abattis Bioceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Abattis Bioceuticals is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Abattis Bioceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Abattis Bioceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ATT Future Performance

 How is Abattis Bioceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Abattis Bioceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
76.2%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Abattis Bioceuticals expected to grow at an attractive rate?
  • Unable to compare Abattis Bioceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Abattis Bioceuticals's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Abattis Bioceuticals's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:ATT Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 76.2%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 50%
Canada Market Earnings Growth Rate Market Cap Weighted Average 17.4%
Canada Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:ATT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:ATT Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-06-30 0 -7 -28
2018-03-31 0 -4 -22
2017-12-31 -4 -12
2017-09-30 -1 -8
2017-06-30 0 -1 -5
2017-03-31 0 -1 -4
2016-12-31 0 -1 -3
2016-09-30 -1 -2
2016-06-30 0 -1 -4
2016-03-31 0 -2 -4
2015-12-31 0 -1 -4
2015-09-30 0 -2 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Abattis Bioceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Abattis Bioceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:ATT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Abattis Bioceuticals Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ATT Past Financials Data
Date (Data in CAD Millions) EPS *
2018-06-30 -0.10
2018-03-31 -0.11
2017-12-31 -0.07
2017-09-30 -0.05
2017-06-30 -0.04
2017-03-31 -0.03
2016-12-31 -0.03
2016-09-30 -0.02
2016-06-30 -0.05
2016-03-31 -0.05
2015-12-31 -0.06
2015-09-30 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Abattis Bioceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Abattis Bioceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Abattis Bioceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Abattis Bioceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Abattis Bioceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Abattis Bioceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ATT Past Performance

  How has Abattis Bioceuticals performed over the past 5 years?

  • Abattis Bioceuticals's last earnings update was 247 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Abattis Bioceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Abattis Bioceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Abattis Bioceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Abattis Bioceuticals's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Abattis Bioceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Abattis Bioceuticals Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ATT Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 0.01 -27.58 24.30 0.03
2018-03-31 0.01 -22.09 20.80 0.03
2017-12-31 -11.85 11.32 0.04
2017-09-30 -7.63 6.16 0.02
2017-06-30 0.00 -4.69 4.65 0.03
2017-03-31 0.00 -3.59 3.47 0.03
2016-12-31 0.00 -2.89 2.69 0.02
2016-09-30 -2.34 2.09 0.04
2016-06-30 0.02 -3.85 1.86 0.05
2016-03-31 0.03 -4.08 2.02 0.05
2015-12-31 0.08 -4.18 2.41 0.07
2015-09-30 0.09 -4.47 2.80 0.08
2015-06-30 0.08 -3.16 3.08 0.12
2015-03-31 0.07 -3.43 3.44 0.14
2014-12-31 0.02 -8.07 7.65 0.13
2014-09-30 0.01 -7.57 7.05 0.13
2014-06-30 0.00 -6.76 6.42 0.11
2014-03-31 0.02 -6.13 5.74 0.12
2013-12-31 0.02 -1.04 0.76 0.13
2013-09-30 0.02 -1.10 0.81 0.12
2013-06-30 0.02 -1.37 1.04 0.17
2013-03-31 -1.30 1.02 0.16
2012-12-31 -1.20 0.98 0.14
2012-09-30 -0.99 0.80 0.12
2012-06-30 -0.81 0.86 0.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Abattis Bioceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Abattis Bioceuticals has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Abattis Bioceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Abattis Bioceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Abattis Bioceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ATT Health

 How is Abattis Bioceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Abattis Bioceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Abattis Bioceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Abattis Bioceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Abattis Bioceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 9.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Abattis Bioceuticals Company Filings, last reported 10 months ago.

CNSX:ATT Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 68.71 0.84 6.36
2018-03-31 68.60 0.81 19.45
2017-12-31 10.78 0.00 8.85
2017-09-30 0.77 0.00 0.53
2017-06-30 1.91 0.00 0.87
2017-03-31 1.01 0.03 0.49
2016-12-31 1.01 0.03 0.46
2016-09-30 0.21 0.03 0.04
2016-06-30 0.54 0.00 0.00
2016-03-31 0.38 0.00 0.04
2015-12-31 0.72 0.00 0.35
2015-09-30 0.48 0.00 0.25
2015-06-30 2.97 0.00 0.18
2015-03-31 3.51 0.00 0.64
2014-12-31 3.96 0.00 0.46
2014-09-30 4.64 0.00 1.11
2014-06-30 4.92 0.00 2.72
2014-03-31 4.84 0.29 3.45
2013-12-31 0.40 0.29 0.00
2013-09-30 0.56 0.29 0.01
2013-06-30 0.78 0.26 0.00
2013-03-31 1.02 0.25 0.02
2012-12-31 1.11 0.17 0.01
2012-09-30 0.62 0.16 0.01
2012-06-30 0.33 0.00 0.01
  • Abattis Bioceuticals's level of debt (1.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (33.4% vs 1.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Abattis Bioceuticals has less than a year of cash runway based on current free cash flow.
  • Abattis Bioceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 52% each year.
X
Financial health checks
We assess Abattis Bioceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Abattis Bioceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ATT Dividends

 What is Abattis Bioceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Abattis Bioceuticals dividends.
If you bought CA$2,000 of Abattis Bioceuticals shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Abattis Bioceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Abattis Bioceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:ATT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 331 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Abattis Bioceuticals has not reported any payouts.
  • Unable to verify if Abattis Bioceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Abattis Bioceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Abattis Bioceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Abattis Bioceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Abattis Bioceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Abattis Bioceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ATT Management

 What is the CEO of Abattis Bioceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rob Abenante
COMPENSATION CA$375,648
TENURE AS CEO 2.1 years
CEO Bio

Mr. Robert Abenante, also known as Rob, has been the Chief Executive Officer and President of Abattis Bioceuticals Corp. since April 07, 2017. Mr. Abenante is a seasoned executive with extensive public company experience. After his tenures with Price- waterhouseCoopers and Deloitte, he founded and/or served as an officer/director of several public and private companies across various industries, ranging from energy and mining to agriculture technology and nutraceuticals. He has been a Director of Abattis Bioceuticals Corp. since May 29, 2017. Mr. Abenante is a Chartered Professional Accountant (CPA, CA) who also holds a Masters.

CEO Compensation
  • Insufficient data for Rob to compare compensation growth.
  • Rob's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure and age of the Abattis Bioceuticals management team in years:

1.5
Average Tenure
47
Average Age
  • The average tenure for the Abattis Bioceuticals management team is less than 2 years, this suggests a new team.
Management Team

Rob Abenante

TITLE
President
COMPENSATION
CA$376K
TENURE
2.1 yrs

Douglas Sorocco

TITLE
COMPENSATION
CA$124K
AGE
47
TENURE
2 yrs

Guy Dancosse

TITLE
COMPENSATION
CA$146K
AGE
74
TENURE
2 yrs

Francesco Paolini

TITLE
CFO & Director
TENURE
0.1 yrs

Patrick Mitchell

TITLE
Chief Operating Officer
TENURE
0.5 yrs

Shawn Balaghi

TITLE
Head of Corporate Development
TENURE
1 yrs

Clayton Chessa

TITLE
Head of Operations
TENURE
1.9 yrs

Jim Carter

TITLE
Head of Mergers and Acquisitions Advisory
TENURE
1 yrs

Chris Cherry

TITLE
Corporate Comptroller
AGE
39
TENURE
2.7 yrs

Nicole Breitinger

TITLE
Corporate Secretary
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure of the Abattis Bioceuticals board of directors in years:

1
Average Tenure
  • The average tenure for the Abattis Bioceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rob Abenante

TITLE
President
COMPENSATION
CA$376K
TENURE
2 yrs

Francesco Paolini

TITLE
CFO & Director
TENURE
0.1 yrs

Brazos Arthur Minshew

TITLE
Head of the Medical Advisory Board
TENURE
1 yrs

Peter Gordon

TITLE
Director
COMPENSATION
CA$100K
TENURE
2 yrs

Cedric Wilson

TITLE
Director
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
10. Aug 18 Buy Robert Abenante Individual 18. Jun 18 18. Jun 18 4,677,625 CA$0.15 CA$684,336
03. Aug 18 Sell James Irving Individual 01. Aug 18 01. Aug 18 -236,000 CA$0.15 CA$-35,400
21. Jun 18 Sell Crimson Opportunities Ltd. Company 19. Jun 18 19. Jun 18 -1,000,000 CA$0.17 CA$-170,000
X
Management checks
We assess Abattis Bioceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Abattis Bioceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ATT News

Simply Wall St News

ATT Company Info

Description

Abattis Bioceuticals Corp., a biotechnology company, researches, develops, licenses, and markets ingredients and formulas for use in the biopharma, nutraceutical, cosmetic, and animal nutrition markets in Canada. It is also involved in the possession of cannabis and related active ingredients, as well as the production of extracts; and marketing services. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corporation in September 2012. Abattis Bioceuticals Corp. was incorporated in 1997 and is headquartered in Vancouver, Canada.

Details
Name: Abattis Bioceuticals Corp.
ATT
Exchange: CNSX
Founded: 1997
€29,470,264
467,029,027
Website: http://www.abattis.com
Address: Abattis Bioceuticals Corp.
970 Burrard Street,
Suite 244,
Vancouver,
British Columbia, V6Z 2R4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB 115 Common Shares Deutsche Boerse AG DE EUR 13. Apr 2011
MUN 115 Common Shares Boerse Muenchen DE EUR 13. Apr 2011
CNSX ATT Common Shares Canadian National Stock Exchange CA CAD 13. Apr 2011
Number of employees
Current staff
Staff numbers
0
Abattis Bioceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/03 02:58
End of day share price update: 2019/02/04 00:00
Last earnings filing: 2018/08/29
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.